Find in Library

877 Intermittent dosing of the ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib promotes antitumor immunity by remodelling the tumor immune microenvironment in pre-clinical models

oleh: Matthew King, Dmitry Gabrilovich, Simon Barry, Mark Cobbold, Viia Valge-Archer, Adina Hughes, Elizabeth Hardaker, Alison Peter, Anisha Solanki, Lukasz Magiera, Gozde Kar, Stephen Fawell, Ankur Karmokar, Marta Milo, Chrysiis Michaloglou, Ricardo Miragaia, Sara Talbot, Carolyn Lam, Daniel Sutton, Scott Hoffmann, Larissa Carnevalli, Zena Wilson, Alan Lau